5XYY

The structure of p38 alpha in complex with a triazol inhibitor

5XYY の概要

• エントリーDOI: 10.2210/pdb5xyy/pdb
• 分子名称: Mitogen-activated protein kinase 14, 3-(5-{[(2-chloro-6-fluorophenyl)methyl]amino}-4H-1,2,4-triazol-3-yl)phenol (3 entities in total)
• 機能のキーワード: p38 map kinase, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• 由来する生物種: Homo sapiens (human)
• 細胞内の位置: Cytoplasm : Q16539
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 43833.28

構造登録者

Wang, Y.L.,Sun, Y.Z.,Cao, R.,Liu, D.,Li, L.,Qi, X.B.,Huang, N. (登録日: 2017-07-11, 公開日: 2018-01-17, 最終更新日: 2024-04-10)

主引用文献

Wang, Y.,Sun, Y.,Cao, R.,Liu, D.,Xie, Y.,Li, L.,Qi, X.,Huang, N.
In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery.
J. Med. Chem., 60:8552-8564, 2017

PubMed Abstract: To explore novel kinase hinge-binding scaffolds, we carried out structure-based virtual screening against p38α MAPK as a model system. With the assistance of developed kinase-specific structural filters, we identify a novel lead compound that selectively inhibits a panel of kinases with threonine as the gatekeeper residue, including BTK and LCK. These kinases play important roles in lymphocyte activation, which encouraged us to design novel kinase inhibitors as drug candidates for ameliorating inflammatory diseases and cancers. Therefore, we chemically modified our substituted triazole-class lead compound to improve the binding affinity and selectivity via a "minimal decoration" strategy, which resulted in potent and selective kinase inhibitors against LCK (18 nM) and BTK (8 nM). Subsequent crystallographic experiments validated our design. These rationally designed compounds exhibit potent on-target inhibition against BTK in B cells or LCK in T cells, respectively. Our work demonstrates that structure-based virtual screening can be applied to facilitate the development of novel chemical entities in crowded chemical space in the field of kinase inhibitor discovery.

PubMed: 28945083
DOI: 10.1021/acs.jmedchem.7b01075

実験手法

X-RAY DIFFRACTION (1.7 Å)